Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Evoke Pharma, Inc. (NASDAQ:EVOK) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 21,000 shares, a decrease of 32.7% from the February 28th total of 31,200 shares. Based on an average trading volume of 21,900 shares, the short-interest ratio is presently 1.0 days. Approximately 1.5% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Evoke Pharma in a report on Friday. They set a “sell” rating on the stock.

Evoke Pharma Trading Down 1.6 %

Shares of Evoke Pharma stock traded down $0.05 during trading on Monday, reaching $2.75. The stock had a trading volume of 3,751 shares, compared to its average volume of 120,538. The stock has a fifty day moving average price of $4.25 and a two-hundred day moving average price of $4.63. Evoke Pharma has a 52 week low of $2.50 and a 52 week high of $12.32. The company has a market capitalization of $4.10 million, a price-to-earnings ratio of -0.25 and a beta of 0.12.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). The firm had revenue of $3.31 million during the quarter, compared to the consensus estimate of $3.08 million. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC boosted its stake in Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the period. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 at the end of the most recent quarter.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.